Looking Ahead Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis

Michael Ardern-Jones, BSc, MBBS, DPhil, FRCP; Mark Boguniewicz, MD; Marjolein de Bruin-Weller, MD, PhD


This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Michael Ardern-Jones, BSc, MBBS, DPhil, FRCP
Associate Professor, Consultant Dermatologist
University of Southampton
Southampton, United Kingdom

Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health
and University of Colorado School of Medicine
Denver, Colorado

Marjolein de Bruin-Weller, MD, PhD
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands

Target Audience

The educational design of this activity addresses the needs of allergists, clinical immunologists, and other clinicians involved in the management of patients with moderate-to-severe atopic dermatitis.

Statement of Need

Atopic dermatitis is a common, chronic, inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of this condition can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of disease etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other such therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, participants of this activity will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making.11 In this Evidence-Based Best Practices™ program, a multidisciplinary panel of internationally recognized experts will review the latest published evidence with the goal of providing recommendations to enhance overall patient outcomes. The faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and convey their own clinical experience in managing patients with moderate-to-severe disease.


  1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
  2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
  3. Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7 [Epub ahead of print].
  4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  5. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  6. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  7. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  8. de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
  9. Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
  10. Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3 suppl 1):S53-S62.
  11. Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170.

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Discuss atopic dermatitis pathophysiology, including the mechanistic rationales and clinical evidence for targeted therapies in moderate-to-severe disease
  2. Comprehensively evaluate patients with atopic dermatitis over time for uncontrolled symptoms, sleep disturbances, quality-of-life impairment, and comorbid conditions
  3. Tailor treatment regimens for patients with moderate-to-severe atopic dermatitis based on disease severity, presence of comorbid conditions, and response to prior therapy
  4. Partner with patients and caregivers to improve their recognition of flare triggers, increase treatment adherence, and promote shared decision-making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Michael Ardern-Jones, BSc, MBBS, DPhil, FRCP: Grant/Research Support: AbbVie Inc.; Honoraria: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme; Speakers Bureau: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

Mark Boguniewicz, MD: Consultant/Advisor: Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Grant/Research Support: Regeneron Pharmaceuticals, Inc.; Speakers Bureau: Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme

Marjolein de Bruin-Weller, MD, PhD: Consultant/Advisor: AbbVie Inc., Sanofi Genzyme, Regeneron Pharmaceuticals, Inc.; Grant/Research Support: AbbVie Inc., LEO Pharma, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 09/10/2020

type Webcast